Craft

Scopus BioPharma

Stock Price

$0

2024-10-29

Market Capitalization

$21 K

2024-10-29

Scopus BioPharma Summary

Company Summary

Overview
Scopus BioPharma (formerly known as Project18) is a biopharmaceutical company developing therapeutics targeting diseases with unmet medical needs. Its lead drug candidate is a targeted immuno-oncology gene therapy for the treatment of multiple cancers. The company also develops additional new chemical entities to treat other serious diseases, including systemic sclerosis.
Type
Public
Status
Active
Founded
2017
HQ
New York, NY, US | view all locations
Website
https://scopusbiopharma.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Robert J. Gibson

    Robert J. Gibson, Vice Chairman and Director

  • Ashish P. Sanghrajka

    Ashish P. Sanghrajka, President and Director

  • Joshua R. Lamstein

    Joshua R. Lamstein, Chairman and Director

Operating MetricsView all

Pre-Clinical Phase Products

1

Q2, 2020

Phase I Trials Products

1

Q2, 2020

LocationsView all

1 location detected

  • New York, NY HQ

    United States

    420 Lexington Ave

Scopus BioPharma Financials

Summary Financials

Net income (Q2, 2023)
($2.9M)
Cash (Q2, 2023)
$362.1K
EBIT (Q2, 2023)
($2.9M)

Footer menu